ABSTRACT INTRODUCTION: Since the outcomes associated with the use of renin-angiotensin-system inhibitors (RASi) by hemodialysis (HD) patients are not fully known, we investigated their effect on the cardiovascular mortality of chronic HD patients. METHODS: Data from 388 HD patients (237 men and 151 women) who were routinely treated for at least 6 months were analyzed. Treatment with a RASi was the major predictor variable. The main outcome measure was cardiovascular mortality. Cox regression analysis was used to assess for the use of RASi and risk of death. RESULTS: Hypertension was diagnosed in 320 patients (82.5%), and 197 (50.8%) of them were treated with a RASi (treated group) and 191 (49.2%) were not (untreated group). The treated group had a higher prevalence of hypertension, history of congestive heart failure, and presence of ST-T changes. Kaplan-Meier analysis revealed a reduction in risk of cardiovascular death in the treated group during the follow-up period (fig. 2; log-rank: p=0.0379). The multivariate analysis showed that treatment with a RASi was also independently associated with reduced cardiovascular mortality (hazard ratio= 0.184; p=0.0161). CONCLUSIONS: The results of this study suggest a possible association between the treatment with RASi and reduced risk of cardiovascular mortality, independent of their effect of lowering blood pressure.
Cite this paper
nullK. Omae, T. Ogawa, M. Yoshikawa, M. Mitobe and K. Nitta, "Inhibition of the Renin-Angiotensin System and Cardiovascular Mortality in Chronic Hemodialysis Patients," International Journal of Clinical Medicine, Vol. 2 No. 2, 2011, pp. 57-63. doi: 10.4236/ijcm.2011.22011.
  E. Villar, L. Remontet, M. Labeeuw and R. Ecochard, “Effect of Age, Gender, and Diabetes on Excess Death in End-Stage Renal Failure,” Journal of American Society of Nephrology, Vol. 18, No. 7, 2007, pp. 2125-2134. doi:10.1681/ASN.2006091048
 R. N. Foley, A. M. Murray, S. Li, et al., “Chronic Kidney Disease and the Risk for Cardiovascular Disease, Renal Replacement, and Death in the United States Medicare Population, 1998-1999,” Journal of American Society of Nephrology, Vol. 16, No. 2, 2005, pp. 489-495.
 A. J. Collins, “Cardiovascular Mortality in End-Stage Renal Disease,” American Journal of Medical Science, Vol. 325, No. 4, 2003, pp.163-167.
 R. N. Foley, P. S. Parfrey, J. D. Harnett, G. M. Kent, D. C. Murray and P. E. Barre, “Impact of Hypertension on Cardiomyopathy, Morbidity and Mortality in End-Stage Renal Disease,” Kidney International, Vol. 49, No. 5, 1996, pp. 1379-1385. doi:10.1038/ki.1996.194
 P. G. Zager, J. Nikolic, R. H. Brown, et al., ” “U” Curve Association of Blood Pressure and Mortality in Hemodialysis Patients,” Kidney International, Vol. 54, No. 2, 1998, pp. 561-569.
 F. K. Port, T. E. Hulbert-Shearon, R. A. Wolfe, et al., “ Predialysis Blood Pressure and Mortality Risk in a National Sample of Maintenance Hemodialysis Patients,” American Journal of Kidney Disease, Vol. 33, No. 3, 1999, pp. 507-517. doi:10.1016/S0272-6386(99)70188-5
 K. Kakantar-Zadeh, R. D. Kilpatrick, C. J. McAllister, S. Greenland and J. D. Kopple, “Reverse Epidemiology of Hypertension and Cardiovascular Death in the Hemodialysis Population: the 58th Annual Fall Conference and Scientific Sessions,” Hypertension Vol. 45, No. 4, 2005, pp. 811-817. doi:10.1161/01.HYP.0000154895.18269.67
 R. Agarwal, “Hypertension and Survival in Chronic Hemodialysis Patients-Past Lessons and Future Opportunities,” Kidney International, Vol. 67, No. 1, 2005, pp. 1-13. doi:10.1111/j.1523-1755.2005.00050.x
 Z. Li, E. Jr. Lacson, E. G. Lowrie, et al., “The Epidemiology of Systolic Blood Pressure and Death Risk in Hemodialysis Patients,” American Journal of Kidney Disease, Vol. 48, No. 4, 2006, pp. 606-615.
 F. Zannad, M. Kessler, P. Lehert, et al., “Prevention of Cardiovascular Events in End-Stage Renal Disease: Results of a Randomized Trial of Fosinopril and Implications for Future Studies,” Kidney International, Vol. 70, No. 7, 2006, pp.1318-1324. doi:10.1038/sj.ki.5001657
 A. Takahashi, H. Takase, T. Toriyama, et al., “Candesartan, an Angiotensin II Type-1 Receptor Blocker, Reduces Cardiovascular Events in Patients on Chronic Haemodialysis Patients-a Randomized Study,” Nephrology Dialysis Transplantation, Vol. 21, No. 9, 2006, pp. 2507-2512. doi:10.1093/ndt/gfl293
 H. Suzuki, Y. Kanno, S. Sugahara, et al., “Effect of Angiotensin Receptor Blockers on Cardiovascular Events in Patients Undergoing Hemodialysis: an Open-Label Randomized Controlled Trial,” American Journal of Kidney Disease, Vol. 52, No. 3, 2008, pp. 501-506.
 G. Cice, L. Ferrara, A. D’Andrea, et al., “Carvedilol Increases Two-Year Survivalian Dialysis Patients with Dilated Cardiomyopathy: A Prospective, Placebo-Con- trolled Trial,” Journal of American College of Cardiology, Vol. 41, No. 9, 2003, pp. 1438-1444.
 M. Tepel, W. Hopfenmueller, A. Scholze, A. Maier and W. Zidek, “Effect of Amlodipine on Cardiovascular Events in Hypertensive Hemodialysis Patients,” Nephrology Dialysis Transplantation, Vol. 23, No. 11, 2008, pp. 3605-3612. doi:10.1093/ndt/gfn304
 P. Roy, J. Bouchard, R. Amyot and F. Madore, “Prescription Patterns of Pharmacological Agents for Left Ventricular Systolic Dysfunction among Hemodialysis Patients,” American Journal of Kidney Disease, Vol. 48, No. 4, 2006, pp. 645-651. doi:10.1053/j.ajkd.2006.06.006
 W. C. Winkelmayer, R. Levin and S. Setoguchi, “Associations of Kidney Function with Cardiovascular Medication Use after Myocardial Infarction,” Clinical Journal of American Society of Nephrology, Vol. 3, No. 5, 2008, pp. 1415-1422. doi:10.2215/CJN.02010408
 R. N. Foley, P. S. Parfrey, J. D. Harnett, G. M. Kent, D. C. Murray and P. E. Barre, “Hypoalbuminemia, Cardiac morbidity, and Mortality in End-Stage Renal Disease,” Journal of American Society of Nephrology, Vol. 7, No. 5, 1996, pp. 728-736.
 P. W. Macfarlane and S. Latif, “Automated Serial ECG Comparison Based on the Minnesota Code,” Journal of Electrocardiology, Vol. 29, Suppl. 1, 1996, pp. 29-34.
 K. G. Alberti and P. Z. Zimmet, “Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus Provisional Report of a WHO Consultation,” Diabetes Medicine, Vol. 15, No. 7, 1998, pp. 539-553. doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
 J. J. De Lima, H. Abensur, E. M. Krieger and F. Pileggi, “Arterial Blood Pressure and Left Ventricular Hypertrophy in Haemodialysis Patients,” Journal of Hypertension, Vol. 14, No. 8, 1996, pp. 1019-1024.
 H. J. Heerspink, T. Ninomiya, S. Zoungar, et al., “Effect of Lowering Blood Pressure on Cardiovascular Events and Mortality in Patients on Dialysis: a Systematic Review and Meta-Analysis,” The Lancet, Vol. 373, No. 9668, 2009, pp. 1009-1015.
 R. Agarwal and A. D. Sinha, “Cardiovascular Protection with Antihypertensive Drugs in Dialysis Patients: Systematic Review and Meta-Analysis,” Hypertension, Vol. 53, No. 5, 2009, pp. 860-866.
 J. M. Lopez-Gomez, M. M. Villaverde, R. Jofre, P. Rodriguez-Benitez and R. Perez-Garcia, “Interdialysis Weight gain as a Marker of Blood Pressure, Nutrition, and Survival in Hemodia1ysis Patients,” Kidney International, Vol. 93, Suppl., 2005, pp. 63-68.
 “Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009).” Guidelines subcommittee of the Japanese Society of Hypertension. Tokyo, Japan, 2009.
 A. V. Chobanian, G. L. Bakris, H. R. Black, et al., “Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure,” Hypertension , Vol. 42, No. 6, 2003, pp. 1206- 1252. doi:10.1161/01.HYP.0000107251.49515.c2
 U. M. Khosla and R. J. Johnson, “Hypertension in the Hemodialysis Patients and the “Lag Phenomenon”: Insights into Pathophysiology and Clinical Management, American Journal of Kidney Disease, Vol. 43, No. 4, 2004, pp. 739-808. doi:10.1053/j.ajkd.2003.12.036
 P. Zucchelli, A. Santoro and A. Zuccala, “Genesis and Control of Hypertension in Hemodialysis Patients,” Seminar in Nephrology, Vol. 8, No. 2, 1988, pp. 163-168.
 P. A. McCullough, K. R. Sandberg, J. Yee and M. P. Hudson, “Mortality Benefit of Angiotensin-Converting Enzyme Inhibitors after Cardiac Events in Patients with End-Stage Renal Disease,” Journal of Renin-Angio- tensin-Aldosterone System, Vol. 3, No. 3, 2002, pp. 188-191. doi:10.3317/jraas.2002.040
 A. K. Berger, S. Duval and H. M. Krumholz, “Aspirin, beta-Blocker, and Angiotensin-Converting Enzyme Inhibitor Therapy in Patients with End-Stage Renal Disease and an Acute Myocardial Infarction,” Journal of American College of Cardiology, Vol. 42, No. 2, 2003, pp. 201-208. doi:10.1016/S0735-1097(03)00572-2
 S. Efrati, R. Zaidenstein, V. Dishy V, et al., “ACE Inhibitors and Survival of Hemodialysis Patients,” American Journal of Kidney Disease, Vol. 40, No. 5, 2002, pp. 1023-1029. doi:10.1053/ajkd.2002.36340
 F. Zannad, M. Kessler, P. Lehert P, et al., “Prevention of Cardiovascular Events in End-Stage Renal Disease: Results of a Randomized Trial of Fosinopril and Implications for Future Studies,” Kidney International, Vol. 70, No. 7, 2006, pp. 1318-1324. doi:10.1038/sj.ki.5001657
 W. Fang, D. G. Oreopulos and J. M. Bargman, “Use of ACE Inhibitors or Angiotensin Receptor Blockers and Survival in Patients on Peritoneal Dialysis,” Nephrology Dialysis Transplantation, Vol. 23, No. 11, 2008, pp. 3704-3710. doi:10.1093/ndt/gfn321
 I. Kolesnyk, M. Noodzij, F. W. Dekker, E. W. Boeschoten and R. T. Krediet, “A Positive Effect of AII Inhibitors on Peritoneal Membrane Function in Long-Term PD Patients,” Nephrology Dialysis Transplantation, Vol. 24, No. 1, 2008, pp. 272-277. doi:10.1093/ndt/gfn421
 K. Iseki, T. Shoji, S. Nakai, et al., “Higher Survival Rates of Chronic Hemodialysis Patients on Anti-Hypertensive Drugs,” Nephron Clinical Practice, Vol. 113, No. 3, 2009, pp 183-190. doi:10.1159/000232600